Endometrial Cancer Clinical Trials in Austin, Texas

15 studies are recruiting for endometrial cancer in Austin, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

   The purpose of this study is to determine the safety and tolerability of monotherapy CR-002 and to identify the MTD and/or optimal biologic dose and RP2D(s) in participants with locally advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Clinical Study Site, Austin, Texas

   Locations

   3 in total

   Run by

   Crescent Biopharma, Inc.

   See if you can join NCT07909031 on ClinicalTrials.gov

2. Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer

   This study is being conducted to assess whether the study medicine PF 08634404, given in combination with chemotherapy, improves outcomes compared with another medicine called pembrolizumab plus chemotherapy. Chemotherapy is a type of cancer treatment that uses medicines to destroy cancer cells or …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Texas Oncology - Central South, Austin, Texas

   Locations

   54 in total

   Run by

   Pfizer

   See if you can join NCT07578649 on ClinicalTrials.gov

3. A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

   This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology, Austin, Texas

   Locations

   25 in total

   Run by

   Terremoto Biosciences Inc.

   See if you can join NCT07109726 on ClinicalTrials.gov

4. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

   This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Texas Oncology - Central/South Texas, Austin, Texas

   Locations

   88 in total

   Run by

   Artios Pharma Ltd

   See if you can join NCT04657068 on ClinicalTrials.gov

5. A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

   This is a Phase 1, two-part, open-label, nonrandomized, dose-escalation and signal-seeking study of CGT6297, evaluating the safety, tolerability, PK, pharmacodynamic (what the drug does to the body), and antitumor activity of CGT6297 in adult participants with advanced solid tumors harboring PIK3CA…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Austin, Austin, Texas

   Locations

   12 in total

   Run by

   Cogent Biosciences, Inc.

   See if you can join NCT07383506 on ClinicalTrials.gov

6. DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

   DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by BICR, in participant…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Austin, Texas

   Locations

   257 in total

   Run by

   AstraZeneca

   See if you can join NCT06989112 on ClinicalTrials.gov

7. Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

   This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Texas Oncology - Central / South Texas, Austin, Texas

   Locations

   66 in total

   Run by

   Genmab

   See if you can join NCT05579366 on ClinicalTrials.gov

8. Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

   The purpose of this study is to compare how well Rina-S (GEN1184) works compared to treatment of physician's choice (paclitaxel or doxorubicin) that are considered standard medical care for the treatment of recurrent or progressive endometrial cancer (EC) following prior therapy. There is an equal …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   USOR - Texas Oncology, Austin, Texas

   Locations

   177 in total

   Run by

   Genmab

   See if you can join NCT07166094 on ClinicalTrials.gov

9. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   New Experimental Therapeutics - NEXT Oncology, Austin, Texas

   Locations

   76 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

10. A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

    This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts: * Part 1A is a dose escalation study of STRO-004 monotherapy in selected tumor types known to commonly express Tissue Factor (TF). * Part 1B is a coh…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Austin, Austin, Texas

    Locations

    9 in total

    Run by

    Sutro Biopharma, Inc.

    See if you can join NCT07227168 on ClinicalTrials.gov

11. Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

    HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody drug conjugate (ADC), in adult participants with advanced or metastatic solid tumors known to be expressing PTK7. The study employs a sequential dose…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Oncology - Austin, Austin, Texas

    Locations

    12 in total

    Run by

    Whitehawk Therapeutics, Inc.

    See if you can join NCT07444814 on ClinicalTrials.gov

12. Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

    This is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician's choice of chemotherapy (doxorubicin or paclitaxel) in participants with B7-H4 selected advanced/metastatic EC that progressed following pla…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Research Site, Austin, Texas

    Locations

    320 in total

    Run by

    AstraZeneca

    See if you can join NCT07044336 on ClinicalTrials.gov

13. cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

    This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gast…

    Stage

    Not phased

    Ages

    40 and older

    Site

    Elligo Health Research, Inc., Austin, Texas

    Locations

    17 in total

    Run by

    Adela, Inc

    See if you can join NCT05366881 on ClinicalTrials.gov

14. A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

    A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Dren Investigational Site, Austin, Texas

    Locations

    10 in total

    Run by

    Dren Bio

    See if you can join NCT06999187 on ClinicalTrials.gov

15. Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

    This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have achieved complete response or partial response on chemotherapy. The study will be conducted in 2 parts. Part 1 will evaluate safety and efficacy of two different doses …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Texas Oncology-Austin Central, Austin, Texas

    Locations

    83 in total

    Run by

    Kartos Therapeutics, Inc.

    See if you can join NCT05797831 on ClinicalTrials.gov